Complete report $9,800. DataPack (test volumes, sales forecasts, supplier shares) $6,400.
New Frontiers in the U.S. Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the U.S. cancer diagnostics market during the nextfive years. The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
U.S. Market Overview
- Five-year test volume and sales projections.
- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers.
- Estimated universe of laboratories performing cancer diagnostic testing.
- Cancer statistics, etiology and recent developments.
Business Opportunities and Strategic Recommendations
- Specific new product development opportunities with potentially
significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Over 200 Current and Emerging Cancer Diagnostic Test
- Biochemical Markers
- Growth Factors
- Colony Stimulating Factors
- Immunohistochemical Stains, and others.
- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.
Supplier Shares, Sales and Volume Forecasts
- Sales and market shares of major cancer diagnostic product
suppliers by individual test.
- Five-year test volume and sales forecasts
for major tumor markers by market segment, including:
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Analysis of major molecular diagnostic and immunodignostic analyzers
used for cancer testing, including their operating characteristics,
features and selling prices.
- Assessment of latest molecular diagnostic methods,
biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,
chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies
and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.
- Extensive listings of companies, universities
and research centers developing new cancer diagnostic tests
and detection technologies.
- Strategic assessments ofmajor suppliers
and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in R&D.
- The companies analyzed in the report include
- Agilent Technologies
- Applied Gene Technologies
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- Correlogic Systems/Vermillion
- Eiken Chemical
- Enzo Biochem
- Exact Sciences
- Guided Therapeutics
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- Nanogen Elitech
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Quest Diagnostics
- Radient Pharmaceuticals
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher/Life Technologies
- Wako Pure Chemicals
Contains 620 pages and 103 tables
SIMILAR MARKET STUDIES
Carbon Monoxide Detectors Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea ...
May 2017 | $2850 | View Details >>
2017 Kuwait Clinical Chemistry and Immunodiagnostic Markets: Volume and Sales Forecasts for 100 Routine and Special Chemistries, Drugs of Abuse, Endocrine Function, Immunoproteins, TDM, and Tumor Marker Tests--Competitive Strategies, Opportunities
This new report from VPGMarketResearch.com is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic markets during the next five years. The report provides specimen, test volume and sales forecasts; compares features of leading analyzers; profiles key competitors; ...
January 2017 | $0 | View Details >>
This DataPack contains tables from VPGMarketResearch.com new report, 2016 US Point-of-Care/POC Hematology and Flow Cytometry Markets: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers. For pricing information on DataPack sections or individual tables, please contact Customer Service.
January 2016 | $0 | View Details >>
2015-2019 US Critical Care Diagnostic Testing Market: Ancillary Hospital Locations (ER, OR, ICU) -Competitive Strategies, Supplier Shares, Segment Forecasts, Innovative Technologies, Instrumentation Review
This 973-page report contains 153 tables and provides comprehensive analysis of the diagnostic testing markets outside the main hospital laboratory (ERs, ORs, and ICUs). The report includes analysis of the market dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. We trust, ...
July 2015 | $7500 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research